research use only

Mitapivat PK Activator

Cat.No.S6508

Mitapivat (AG-348) is an activator of a pyruvate kinase PKM2, an enzyme involved in glycolysis.
Mitapivat PKM activator Chemical Structure

Chemical Structure

Molecular Weight: 450.55

Jump to

Quality Control

Batch: Purity: 99.97%
99.97

Solubility

In vitro
Batch:

DMSO : 45 mg/mL (99.87 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 2 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 450.55 Formula

C24H26N4O3S

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1260075-17-9 -- Storage of Stock Solutions

Synonyms AG-348 Smiles C1CC1CN2CCN(CC2)C(=O)C3=CC=C(C=C3)NS(=O)(=O)C4=CC=CC5=C4N=CC=C5

Mechanism of Action

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05675436 Enrolling by invitation
Sickle Cell Anemia|Sickle Cell Thalassemia|Sickle Cell Pain|Hbss|Hbsc|Sickle Beta Thalassemia|Sickle Beta Zero Thalassemia|Sickle Cell Syndrome Variant
National Heart Lung and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)
May 15 2024 --
NCT05935202 Not yet recruiting
Hereditary Red Blood Cell Disorder (Disorder)
EuroBloodNet Association
December 21 2023 Phase 2
NCT05610657 Completed
Moderate Hepatic Impairment
Agios Pharmaceuticals Inc.
January 10 2023 Phase 1
NCT05175105 Recruiting
Pediatric Pyruvate Kinase Deficiency|Pediatric Hemolytic Anemia
Agios Pharmaceuticals Inc.
June 6 2022 Phase 3
NCT05144256 Active not recruiting
Pediatric Pyruvate Kinase Deficiency|Pediatric Hemolytic Anemia
Agios Pharmaceuticals Inc.
June 8 2022 Phase 3
NCT05031780 Recruiting
Sickle Cell Disease
Agios Pharmaceuticals Inc.
February 11 2022 Phase 2|Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.